• Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess® (RelabotulinumtoxinA) highlighting its rapid onset of action as early as day one and sustained high patient satisfaction beyond six months1,2  

Lausanne, Switzerland – June 1, 2018 – Galderma today released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve ‘clear’ (IGA 0) skin*.

• Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the European Union (EU)^1-4
• Prurigo nodularis is a serious skin disease characterized by chronic itch, skin nodules covering large body areas, and poor sleep quality, which is es

Ad hoc announcement pursuant to Art. 53 LR

Ad hoc announcement pursuant to Art. 53 LR

Zug, Switzerland, July 24, 2025 – Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2025.